Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection
2019 in Review – Major Acquisitions, Population Studies, Gigantic Founding Rounds, Technological Advancements, and ….
Nebion Provides Curated Omics Data Combined with Innovative Visualizations for Target Discovery, Indication Finding, and Drug Safety Assessment